Related Experiment Video
Updated: Feb 20, 2026
Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
Exploring the crizotinib resistance mechanism of NSCLC with the L1196M mutation using molecular dynamics simulation
Maryam Kay1, Fariba Dehghanian2
1Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Islamic Republic of Iran. maryam_kay2001@yahoo.com.
Abstract:
Crizotinib is an anticancer tyrosine kinase inhibitor that is approved for use as a first-line treatment for some non-small-cell lung cancers. L1196M is the most frequently observed mutation in NSCLC patients. This mutation, known as the gatekeeper mutation in the ALK kinase domain, confers resistance to crizotinib by sterically blocking the binding of the drug. However, the molecular mechanism of crizotinib resistance caused by the L1196M mutation is still unclear. Molecular dynamics simulation was therefore utilized in this study to investigate the mechanism by which the L1196M mutation may affect crizotinib resistance. Our results suggest that larger fluctuations in some important regions of the mutant complex compared to the wild-type complex may contribute to the resistance of the mutant complex to crizotinib. Also, mutation-induced alterations to the secondary structure of the complex as well as unstable hydrogen-bonding patterns in the A-loop and P-loop regions decrease the total binding energy of the complex. This study therefore provides a molecular explanation for the resistance to crizotinib caused by the L1196M mutation, which could aid the design of more efficient and selective drugs.
Insights
The L1196M mutation in non-small cell lung cancer (NSCLC) causes resistance to crizotinib by altering protein structure and stability. This molecular insight could help develop better ALK inhibitors.
Area of Science:
- Biochemistry
- Molecular Biology
- Computational Chemistry
Background:
- Crizotinib is an anticancer drug targeting anaplastic lymphoma kinase (ALK).
- The L1196M mutation in ALK is a common cause of resistance to crizotinib in non-small cell lung cancer (NSCLC).
- The precise molecular mechanism of L1196M-induced crizotinib resistance remains unclear.
Purpose of the Study:
- To investigate the molecular mechanism by which the L1196M mutation confers resistance to crizotinib.
- To provide a molecular explanation for crizotinib resistance in NSCLC patients with the L1196M mutation.
Main Methods:
- Molecular dynamics (MD) simulations were employed to compare the wild-type and L1196M mutant ALK complexes.
- Analysis focused on structural fluctuations, secondary structure alterations, and hydrogen-bonding patterns.
Main Results:
- The L1196M mutation led to increased fluctuations in key regions of the ALK complex.
- Mutation-induced changes in secondary structure and unstable hydrogen bonds (A-loop, P-loop) were observed.
- These alterations resulted in a decreased binding energy between crizotinib and the mutant ALK.
Conclusions:
- The L1196M mutation confers crizotinib resistance through structural destabilization and altered binding interactions.
- Understanding these molecular details can guide the development of novel ALK inhibitors with improved efficacy and selectivity.
- This study offers a molecular basis for overcoming crizotinib resistance in NSCLC.
More Related Videos
12:40A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
